… oxaliplatin dosing in cancer patients with hepatic impairment, we initiated this dose-escalating, …
of single-agent oxaliplatin in patients with hepatic dysfunction as defined by the following …

… oxaliplatin dosing guidelines in renally impaired patients have … Therefore, we initiated this
dose-escalating pharmacokinetic … Dose-escalating and pharmacological study of oxaliplatin in …

… in oxaliplatin elimination, we conducted a dose-escalating … Institute's Organ Dysfunction
Working Group. In this … in each organ dysfunction group, except for group A where at least 12 …

… bile, and as such patients with impaired hepatic function were … dosing in patients with cancer
with hepatic dysfunction was … for pharmacologic analysis.) during the conduct of the study. …

… Patients were assigned to four hepatic function groups … the National Cancer Institute Organ
Dysfunction Working Group … to treatment in a patient in the mild hepatic impairment group …

… Hepatic dysfunction was categorized as mild, moderate, or severe by the National Cancer
Institute Organ Dysfunction Working Group criteria. Fifteen patients with normal liver function …

… Oxaliplatin PKs in patients with impaired liver function were … Working Group is leading an
effort to formally assess … I dose-escalating studies evaluate different cohorts of patients defined …

… with solid tumors and variable hepatic function including … Organ Dysfunction Working Group
study of patients with solid … Oxaliplatin had a poor response rate in prior pediatric studies, …

… Organ Dysfunction Working Group's hepatic impairment categorization and two drug-induced
liver … scores of hepatic function, such as the Model for End-Stage Liver Disease or Child–…

… This study was undertaken to determine the safety, dose-limiting toxicities (DLT), … in cancer
patients with renal impairment and to develop dosing guidelines for imatinib in such patients. …